Jian Jin, PhD
- PROFESSOR | Pharmacological Sciences
- PROFESSOR | Oncological Sciences
- PROFESSOR | Neuroscience
Research Topics:
Cancer, Chromatin, Drug Design and Discovery, Epigenetics, Membrane Proteins/Channels, Neuroscience, Protein Degradation, Structural BiologyDr. Jian Jin is currently the Mount Sinai Endowed Professor in Therapeutics Discovery and Director of the Mount Sinai Center for Therapeutics Discovery at Icahn School of Medicine at Mount Sinai (Mount Sinai). He is also a tenured professor in Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience and a Co-Leader of the Cancer Clinical Investigation Program at The Tisch Cancer Institute at Mount Sinai. Dr. Jin is an internationally recognized medicinal chemist and chemical biologist with >25 years of experience in small-molecule drug discovery. His laboratory is a leader in discovering novel degraders targeting oncoproteins, selective inhibitors of histone methyltransferases, and biased ligands of G protein-coupled receptors. Dr. Jin has published >200 peer-reviewed papers and delivered >100 invited talks. He is also an inventor of >70 issued U.S. patents and published international patent applications. In particular, Dr. Jin is one of several inventors of Daprodustat, a hypoxia-inducible factor (HIF) prolyl hydroxylase small-molecule inhibitor, which has been approved in the U.S. and Japan as an oral medication for the treatment of anemia caused by chronic kidney disease. Dr. Jin was elected to the National Academy of Inventors (NAI) as an NAI Fellow in 2022.
Dr. Jin received a Bachelor’s of Science degree in chemistry from University of Science and Technology of China in 1991 and a PhD in organic chemistry from the Pennsylvania State University in 1997. After completing a post-doctoral training at the Ohio State University, Dr. Jin joined GlaxoSmithKline as a medicinal chemist in 1998 and had been a manager of medicinal chemistry from 2003 to 2008. In 2008, Dr. Jin joined the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill (UNC) as an Associate Professor. He had also served as an Associate Director of Medicinal Chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC from 2008 to 2014. Dr. Jin was recruited to Mount Sinai as a professor with tenure in 2014.
Complete list of published work in PubMed
Google scholar citations
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)Education
BS, University of Science and Technology of China
PhD, Pennsylvania State University
Postdoc, Ohio State University
Discovery of Novel Degraders Targeting Oncogenic Proteins
The Jin lab is a leader in developing novel degraders targeting oncogenic proteins. Since 2014, the lab has discovered and characterized a number of first-in-class degraders using the PROTAC (proteolysis targeting chimera) and hydrophobic tagging technologies. Our degrader program has resulted in multiple patent applications filed by Mount Sinai.
Discovery of Biased Ligands for G Protein-coupled Receptors
G protein-coupled receptors (GPCRs) signal not only via canonical pathways involving heterotrimeric large G proteins, but also via non-canonical G protein-independent interactions with other signaling proteins including beta-arrestins. Biased ligands of GPCRs preferentially engage either canonical or non-canonical signaling pathways and are extremely useful tools for elucidating the signal transduction pathways essential for both therapeutic actions and side-effects. The Jin lab has been actively engaged in discovering biased ligands of GPCRs for more than a decade.
Discovery of Selective Inhibitors for Histone Methyltransferases
Histone methyltransferases (HMTs, also known as protein methyltransferases (PMTs)) play critical roles in various human diseases including cancer. The Jin lab has taken a systematic approach to target HMTs for over a decade. By targeting the HMT substrate binding groove, cofactor binding site, and allosteric binding sites, the Jin lab has discovered numerous high quality selective inhibitors of HMTs, which have been widely used by the scientific community.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Jin during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Accent Therapeutics, Inc.; Cullgen, Inc.; EpiCypher, Inc.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Cullgen, Inc.
Royalty Payments:
- Cullgen; Cullgen, Inc.; Cullinan Oncology; KinoDyn Inc. ; LEVO
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.